{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:59Z","timestamp":1785545039520,"version":"3.56.0"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":117,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021\\u2013123508OB-I00"],"award-info":[{"award-number":["PID2021\\u2013123508OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Basque Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000138","name":"U.S. Department of Education","doi-asserted-by":"publisher","award":["IT-1512\\u201322"],"award-info":[{"award-number":["IT-1512\\u201322"]}],"id":[{"id":"10.13039\/100000138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CB\/07\/09\/0008"],"award-info":[{"award-number":["CB\/07\/09\/0008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003451","name":"Euskal Herriko Unibertsitatea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018993","name":"Vital Foundation","doi-asserted-by":"publisher","award":["VITAL21\/17"],"award-info":[{"award-number":["VITAL21\/17"]}],"id":[{"id":"10.13039\/100018993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"Center for International Business Education and Research, University of Illinois at Urbana-Champaign","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.pnpbp.2025.111249","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:14:43Z","timestamp":1736165683000},"page":"111249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review"],"prefix":"10.1016","volume":"136","author":[{"given":"Ines","family":"Erkizia-Santamar\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Horrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Javier","family":"Meana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111249_bb0010","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0091-3057(99)00089-1","article-title":"Increasing the selectivity of drug discrimination procedures","volume":"64","author":"Appel","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111249_bb0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neubiorev.2003.11.012","article-title":"LSD, 5-HT (serotonin), and the evolution of a behavioral assay","volume":"27","author":"Appel","year":"2004","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/02698811231224217","article-title":"Interactions between classic psychedelics and serotonergic antidepressants: effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study","author":"Barbut Siva","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-ht receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111249_bb0035","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1476-5381.1990.tb14138.x","article-title":"Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice","volume":"101","author":"Berendsen","year":"1990","journal-title":"Br. J. Pharmacol."},{"issue":"24","key":"10.1016\/j.pnpbp.2025.111249_bb0055","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm000339w","article-title":"Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines","volume":"43","author":"Blair","year":"2000","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.pnpbp.2025.111249_bb0060","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1007\/s00213-014-3557-7","article-title":"Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes","volume":"231","author":"Blough","year":"2014","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-024-53188-9","article-title":"Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study","volume":"14","author":"Breeksema","year":"2024","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111249_bb0075","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2023.05.008","article-title":"Psychedelics in the treatment of eating disorders: rationale and potential mechanisms","volume":"75","author":"Calder","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic microdosing: prevalence and subjective effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J. Psychoactive Drugs"},{"issue":"7842","key":"10.1016\/j.pnpbp.2025.111249_bb0090","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","article-title":"5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines","volume":"14","author":"Cameron","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"7\u20138","key":"10.1016\/j.pnpbp.2025.111249_bb0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dta.1333","article-title":"Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model","volume":"4","author":"Canal","year":"2012","journal-title":"Drug Test Anal."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-010-1784-0","article-title":"The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen","volume":"209","author":"Canal","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2013.01.007","article-title":"Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model","volume":"70","author":"Canal","year":"2013","journal-title":"Neuropharmacology"},{"issue":"15","key":"10.1016\/j.pnpbp.2025.111249_bb0115","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuropharm.2018.03.010","article-title":"The entropic brain - revisited","volume":"142","author":"Carhart-Harris","year":"2018","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0125","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0130","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/schbul\/sbs117","article-title":"Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis","volume":"39","author":"Carhart-Harris","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111249_bb0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111249_bb0150","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","volume":"184","author":"Casarotto","year":"2021","journal-title":"Cell"},{"issue":"APR 2013","key":"10.1016\/j.pnpbp.2025.111249_bb0155","first-page":"1","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front. Integr. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archpsyc.1960.03590090042008","article-title":"Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy","volume":"2","author":"Chandler","year":"1960","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0165","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00005053-195509000-00001","article-title":"Clinical reactions and tolerance to LSD in chronic schizophrenia","volume":"122","author":"Cholden","year":"1955","journal-title":"J. Nerv. Ment. Dis."},{"issue":"10128","key":"10.1016\/j.pnpbp.2025.111249_bb0170","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111249_bb0175","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2023.1412","article-title":"The intricate interaction between expectations and therapeutic outcomes of psychedelic agents","volume":"80","author":"Colloca","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1476-5381.1963.tb01302.x","article-title":"A method for assessing the effects of drugs on the central actions of 5-Hydroxytryptamine","volume":"20","author":"Corne","year":"1963","journal-title":"Br. J. Pharmacol. Chemother."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1096-9861(19990628)409:2<187::AID-CNE2>3.0.CO;2-P","article-title":"Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat","volume":"409","author":"Cornea-H\u00e9bert","year":"1999","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0091-3057(97)00548-0","article-title":"Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenfluramine-induced head-twitch response in mice","volume":"60","author":"Darmani","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.neuron.2009.04.017","article-title":"Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety\/depression","volume":"62","author":"David","year":"2009","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111249_bb0200","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0205","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1021\/acschemneuro.2c00637","article-title":"Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin","volume":"14","author":"Davoudian","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0210","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111249_bb0215","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/acschemneuro.0c00291","article-title":"Psychedelic-like properties of Quipazine and its structural analogues in mice","volume":"12","author":"De La Fuente Revenga","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2025.111249_bb0220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111249_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.043","article-title":"Psychedelic-inspired drug discovery using an engineered biosensor","volume":"184","author":"Dong","year":"2021","journal-title":"Cell"},{"issue":"June","key":"10.1016\/j.pnpbp.2025.111249_bb0230","article-title":"Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response","volume":"154","author":"Erkizia-Santamar\u00eda","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0235","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2Aand 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0240","article-title":"Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner","author":"Farinha-Ferreira","year":"2024","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0250","article-title":"The non-hallucinogenic serotonin 1B receptor is necessary for the antidepressant-like effects of psilocybin in mice","author":"Fleury","year":"2024","journal-title":"BioRxiv"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0255","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1476-5381.2009.00578.x","article-title":"Functional interactions between 5-HT 2A and presynaptic 5-HT 1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT)","volume":"159","author":"Fox","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","article-title":"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants","volume":"238","author":"Galv\u00e3o-Coelho","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0265","first-page":"1","article-title":"Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: a systematic review","volume":"November","author":"Gattuso","year":"2023","journal-title":"J. Neurochem."},{"issue":"10258","key":"10.1016\/j.pnpbp.2025.111249_bb0270","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0275","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111249_bb0280","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1021\/acschemneuro.8b00186","article-title":"DARK classics in chemical neuroscience: psilocybin","volume":"9","author":"Geiger","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0285","article-title":"A brief historical overview of psychedelic research","volume":"1\u20138","author":"Geyer","year":"2023","journal-title":"Biol. Psych.: Cogn. Neurosci. Neuroimag."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111249_bb0290","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/acsptsci.2c00177","article-title":"Structure\u2212activity relationships for psilocybin, Baeocystin, Aeruginascin, and related analogues to produce pharmacological effects in mice","volume":"5","author":"Glatfelter","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists","volume":"91","author":"Glennon","year":"1983","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111249_bb0300","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.1503\/jpn.240037","article-title":"CCNP innovations in Neuropsychopharmacology award: the psychopharmacology of psychedelics: where the brain meets spirituality","volume":"49","author":"Gobbi","year":"2024","journal-title":"J. Psychiatry Neurosci.: JPN"},{"issue":"December 2019","key":"10.1016\/j.pnpbp.2025.111249_bb0305","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"issue":"26","key":"10.1016\/j.pnpbp.2025.111249_bb0310","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Gonz\u00e1lez-Maeso","year":"2003","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0315","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.pnpbp.2025.111249_bb0320","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111249_bb0325","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0330","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jad.2024.12.061","article-title":"The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression","volume":"372","author":"Goodwin","year":"2025","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111249_bb0335","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine","volume":"41","author":"de Gregorio","year":"2021","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0340","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0345","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0350","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111249_bb0355","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0360","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0370","article-title":"Advancing preclinical chronic stress models to promote therapeutic discovery for human stress disorders","author":"Gyles","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111249_bb0375","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1371\/journal.pbio.0060159","article-title":"Mapping the structural core of human cerebral cortex","volume":"6","author":"Hagmann","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0385","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111249_bb0390","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/0269881110388326","article-title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice","volume":"25","author":"Halberstadt","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"January","key":"10.1016\/j.pnpbp.2025.111249_bb0395","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"issue":"7969","key":"10.1016\/j.pnpbp.2025.111249_bb0400","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-02093-8","article-title":"Australia will be first to prescribe psychedelic drugs for PTSD and depression","volume":"619","author":"Haridy","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0405","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm. Acta Helv."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0410","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","article-title":"Therapeutic mechanisms of psychedelics and entactogens","volume":"49","author":"Heifets","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0415","doi-asserted-by":"crossref","unstructured":"Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021). Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc. Natl. Acad. Sci. USA, 118(17), 0\u20131. Doi: https:\/\/doi.org\/10.1073\/pnas.2022489118.","DOI":"10.1073\/pnas.2022489118"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0420","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0425","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/psymed.2022.0012","article-title":"A single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by adolescent chronic restraint stress without long-term changes in synaptic protein gene expression in a rat experimental system with translational relevance to Depressi","volume":"1","author":"Hibicke","year":"2023","journal-title":"Psychedelic Medicine"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0430","first-page":"1","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"January","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacol.: Off. Public. Am. College Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0435","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of Oral psilocybin Administration in Healthy Participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0440","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3181\/00379727-106-26228","article-title":"Dephosphorylation of psilocybin to psilocin by alkaline phosphatase","volume":"106","author":"Horita","year":"1961","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0445","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0450","series-title":"Mechanisms and Molecular Targets Surrounding the Potential Therapeutic Effects of Psychedelics","first-page":"1","author":"Jaster","year":"2023"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2022.136836","article-title":"Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL\/6J mice","volume":"788","author":"Jaster","year":"2022","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0460","doi-asserted-by":"crossref","DOI":"10.1017\/neu.2019.15","article-title":"Psilocybin lacks antidepressant-like effect in the Flinders sensitive line rat","author":"Jefsen","year":"2019","journal-title":"Acta Neuropsychiatrica."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0465","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0269881120959614","article-title":"Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin","volume":"35","author":"Jefsen","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0470","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0475","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0480","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0485","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-2999(91)90675-G","article-title":"Effects of repeated treatment with 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on the autoregulatory control of dorsal raphe 5-HT neuronal firing and cortical 5-HT release","volume":"200","author":"Kidd","year":"1991","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111249_bb0490","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1038\/s41380-023-02280-z","article-title":"Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats","volume":"28","author":"Kiilerich","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0495","doi-asserted-by":"crossref","DOI":"10.1038\/s44184-024-00068-9","article-title":"A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials","volume":"3","author":"Kishon","year":"2024","journal-title":"Npj Mental Health Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0500","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acsptsci.0c00176","article-title":"Investigation of the structure-activity relationships of psilocybin analogues","volume":"4","author":"Klein","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111249_bb0505","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0510","doi-asserted-by":"crossref","DOI":"10.1177\/0269881118793086","article-title":"Does getting high hurt\u00a0? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016","author":"Leonard","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111249_bb0515","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nat. Mental Health"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/S0028-3908(98)00102-6","article-title":"[3H]MDL 100,907 labels 5-HT 2A serotonin receptors selectively in primate brain","volume":"37","author":"L\u00f3pez-Gim\u00e9nez","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/1096-9861(20010122)429:4<571::AID-CNE5>3.0.CO;2-X","article-title":"Mapping of 5-HT 2A receptors and their mRNA in monkey brain: [3H]MDL100,907 autoradiography and in situ hybridization studies","volume":"429","author":"L\u00f3pez-Gim\u00e9nez","year":"2001","journal-title":"J. Comp. Neurol."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111249_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111249_bb0535","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0540","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/acsptsci.0c00065","article-title":"Transient stimulation with Psychoplastogens is sufficient to initiate neuronal growth","volume":"4","author":"Ly","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0545","doi-asserted-by":"crossref","first-page":"34","DOI":"10.15288\/qjsa.1961.22.034","article-title":"The use of LSD-25 in the treatment of alcoholism and other psychiatric problems","volume":"22","author":"Maclean","year":"1951","journal-title":"Q. J. Stud. Alcohol"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111249_bb0550","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0555","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euroneuro.2021.06.001","article-title":"Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience","volume":"50","author":"Madsen","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0560","article-title":"Unraveling psilocybin\u2019s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression","author":"Magdalena","year":"2024","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0565","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0306-4522(01)00199-3","article-title":"A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex","volume":"105","author":"Marek","year":"2001","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0570","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1523\/JNEUROSCI.21-24-09856.2001","article-title":"Erratum: control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism (the journal of neuroscience (2001) (9856-9866))","volume":"22","author":"Mart\u00edn-Ruiz","year":"2001","journal-title":"J. Neurosci."},{"issue":"10371","key":"10.1016\/j.pnpbp.2025.111249_bb0575","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0580","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12035-011-8175-3","article-title":"Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives","volume":"43","author":"Matthys","year":"2011","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0585","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"McClure-Begley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0590","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0028-3908(90)90001-8","article-title":"Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes","volume":"29","author":"Mckenna","year":"1990","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0600","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078084","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis","author":"Metaxa","year":"2024","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0605","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/npp.2011.13","article-title":"Pharmacological blockade of 5-HT 7 receptors as a putative fast acting antidepressant strategy","volume":"36","author":"Mnie-Filali","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb0610","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111249_bb0615","first-page":"681","article-title":"Dynamic functional Hyperconnectivity after psilocybin intake is primarily associated with oceanic boundlessness","volume":"9","author":"Mortaheb","year":"2024","journal-title":"Biol. Psych.: Cogn. Neurosci. Neuroimag."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0620","article-title":"Ligand bias and inverse agonism on 5-HT2A receptor-mediated modulation of G protein activity in post-mortem human brain","author":"Muneta-Arrate","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0625","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0630","series-title":"Pharmacol, Rev.","first-page":"264","article-title":"Psychedelics","author":"Nichols","year":"2016"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111249_bb0635","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1021\/acschemneuro.8b00043","article-title":"Dark classics in chemical neuroscience: lysergic acid diethylamide (LSD)","volume":"9","author":"Nichols","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0640","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/psymed.2022.0008","article-title":"Proposed consensus statement on defining psychedelic drugs","volume":"1","author":"Nichols","year":"2023","journal-title":"Psychedelic Medicine"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0645","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuroscience.2015.03.050","article-title":"Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex","volume":"297","author":"Nocjar","year":"2015","journal-title":"Neuroscience"},{"issue":"June","key":"10.1016\/j.pnpbp.2025.111249_bb0650","first-page":"1","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)","volume":"10","author":"Nour","year":"2016","journal-title":"Front. Hum. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pbio.1002047","article-title":"Illegal drugs Laws: clearing a 50-year-old obstacle to research","volume":"13","author":"Nutt","year":"2015","journal-title":"PLoS Biol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0660","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs\u2014a new era in psychiatry?","volume":"21","author":"Nutt","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0665","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2023_451","article-title":"Psilocybin and other classic psychedelics in depression","author":"Nutt","year":"2023","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"December 2020","key":"10.1016\/j.pnpbp.2025.111249_bb0670","article-title":"Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice","volume":"401","author":"Odland","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0675","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1124\/pharmrev.122.000590","article-title":"Animal behavior in psychedelic research","volume":"74","author":"Odland","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0680","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: a promising class of plasticity-promoting Neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"J. Exper. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0685","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics May not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0690","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0695","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0306-4522(87)90327-7","article-title":"Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors","volume":"21","author":"Pazos","year":"1987","journal-title":"Neuroscience"},{"issue":"January","key":"10.1016\/j.pnpbp.2025.111249_bb0700","article-title":"Utility of preclinical models in the study of psilocybin \u2013 a comprehensive review","volume":"146","author":"Pedicini","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"23","key":"10.1016\/j.pnpbp.2025.111249_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315284","article-title":"Psychedelic-induced serotonin 2A receptor downregulation does not predict swim stress coping in mice","volume":"23","author":"P\u0119dzich","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0710","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00005053-195402000-00001","article-title":"Clinical reactions of schizophrenics to sodium amytal, pervitin hydrochloride, mescaline sulfate, and d-lysergic acid diethylamide (LSD25)","volume":"119","author":"Pennes","year":"1954","journal-title":"J. Nerv. Ment. Dis."},{"issue":"October","key":"10.1016\/j.pnpbp.2025.111249_bb0715","first-page":"1","article-title":"The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice","volume":"10","author":"Pogorelov","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"May","key":"10.1016\/j.pnpbp.2025.111249_bb0720","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955\u20132021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0725","doi-asserted-by":"crossref","DOI":"10.1177\/02698811241254831","article-title":"Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research","author":"Polito","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111249_bb0730","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11920-022-01361-0","article-title":"Psilocybin efficacy and mechanisms of action in major depressive disorder: a review","volume":"24","author":"Prouzeau","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111249_bb0735","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/cercor\/13.8.870","article-title":"In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents","volume":"13","author":"Puig","year":"2003","journal-title":"Cereb. Cortex"},{"issue":"November 2022","key":"10.1016\/j.pnpbp.2025.111249_bb0740","article-title":"Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice","volume":"222","author":"Qu","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0745","article-title":"Serotonin and schizophrenia","volume":"31","author":"Quednow","year":"2020","journal-title":"Handb. Behav. Neurosci."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111249_bb0750","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"Jama"},{"issue":"MAY","key":"10.1016\/j.pnpbp.2025.111249_bb0755","first-page":"1","article-title":"The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat","volume":"8","author":"Rambousek","year":"2014","journal-title":"Front. Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22020835","article-title":"A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain","volume":"22","author":"Raval","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111249_bb0765","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"August 2023","key":"10.1016\/j.pnpbp.2025.111249_bb0770","article-title":"Safety and risk assessment of psychedelic psychotherapy: a meta-analysis and systematic review","volume":"335","author":"Romeo","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0775","doi-asserted-by":"crossref","DOI":"10.1177\/20503245221085222","article-title":"Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials","volume":"8","author":"Roscoe","year":"2022","journal-title":"Drug Sci. Policy Law"},{"issue":"MAY","key":"10.1016\/j.pnpbp.2025.111249_bb0780","first-page":"1","article-title":"The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers","volume":"8","author":"Roseman","year":"2014","journal-title":"Front. Hum. Neurosci."},{"issue":"JAN","key":"10.1016\/j.pnpbp.2025.111249_bb0785","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0790","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin","volume":"1\u201311","author":"Rosenblat","year":"2024","journal-title":"Med"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111249_bb0795","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0800","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.neuropharm.2011.01.012","article-title":"Irving Page lecture: 5-HT2A serotonin receptor biology: interacting proteins, kinases and paradoxical regulation","volume":"61","author":"Roth","year":"2011","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111249_bb0805","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.20230172","article-title":"Psychedelics as transformative therapeutics","volume":"180","author":"Roth","year":"2023","journal-title":"Am. J. Psychiatry"},{"issue":"23","key":"10.1016\/j.pnpbp.2025.111249_bb0810","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0815","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0820","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6874-5-12","article-title":"An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology","volume":"5","author":"Rybaczyk","year":"2005","journal-title":"BMC Womens Health"},{"issue":"431","key":"10.1016\/j.pnpbp.2025.111249_bb0830","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1192\/bjp.103.431.332","article-title":"Further studies in the therapeutic value of lysergic acid diethylamide in mental illness","volume":"103","author":"Sandison","year":"1957","journal-title":"J. Ment. Sci."},{"issue":"419","key":"10.1016\/j.pnpbp.2025.111249_bb0835","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1192\/bjp.100.419.491","article-title":"The therapeutic value of lysergic acid diethylamide in mental illness","volume":"100","author":"Sandison","year":"1954","journal-title":"J. Ment. Sci."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111249_bb0840","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"issue":"20","key":"10.1016\/j.pnpbp.2025.111249_bb0845","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1016\/j.bmcl.2005.06.104","article-title":"SAR of psilocybin analogs: discovery of a selective 5-HT2C agonist","volume":"15","author":"Sard","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0850","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: from anecdotes and misinformation to systematic science","volume":"36","author":"Schlag","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"40","key":"10.1016\/j.pnpbp.2025.111249_bb0855","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1523\/JNEUROSCI.1665-10.2010","article-title":"Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a \u00df-arrestin2\/Src\/Akt signaling complex in vivo","volume":"30","author":"Schmid","year":"2010","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0860","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1073\/pnas.0708862105","article-title":"Agonist-directed signaling of the serotonin 2A receptor depends on \u03b2-arrestin-2 interactions in vivo","volume":"105","author":"Schmid","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"20","key":"10.1016\/j.pnpbp.2025.111249_bb0865","doi-asserted-by":"crossref","first-page":"8846","DOI":"10.1523\/JNEUROSCI.20-23-08846.2000","article-title":"DOI-induced activation of the cortex: dependence on 5-HT 2A Heteroceptors on Thalamocortical glutamatergic neurons","volume":"23","author":"Scruggs","year":"2000","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0870","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3940(03)00547-0","article-title":"The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats","volume":"346","author":"Scruggs","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0875","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-024-01794-6","article-title":"Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?","author":"Sekssaoui","year":"2024","journal-title":"Neuropsychopharmacol.: Off. Public. Am. College Neuropsychopharmacol."},{"issue":"July","key":"10.1016\/j.pnpbp.2025.111249_bb0880","article-title":"Potential differences in psychedelic actions based on biological sex","volume":"165","author":"Shadani","year":"2024","journal-title":"Endocrinology"},{"issue":"16","key":"10.1016\/j.pnpbp.2025.111249_bb0885","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"issue":"May","key":"10.1016\/j.pnpbp.2025.111249_bb0890","article-title":"Central 5-HT receptors and their function; present and future","volume":"177","author":"Sharp","year":"2020","journal-title":"Neuropharmacology"},{"issue":"8023","key":"10.1016\/j.pnpbp.2025.111249_bb0895","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","article-title":"Psilocybin desynchronizes the human brain","volume":"632","author":"Siegel","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0900","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jnc.15540","article-title":"Molecular insights into psychedelic drug action","volume":"162","author":"Slocum","year":"2022","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111249_bb0905","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"issue":"April","key":"10.1016\/j.pnpbp.2025.111249_bb0910","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroimage.2019.04.009","article-title":"Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects","volume":"196","author":"Smigielski","year":"2019","journal-title":"NeuroImage"},{"issue":"October","key":"10.1016\/j.pnpbp.2025.111249_bb0915","first-page":"1","article-title":"Study protocol for \u201cpsilocybin as a treatment for anorexia nervosa: a pilot study.\u201d","volume":"12","author":"Spriggs","year":"2021","journal-title":"Front. Psychol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12868-022-00766-0","article-title":"Effects of low-doses of methamphetamine on d-fenfluramine-induced head-twitch response (HTR) in mice during ageing and c-fos expression in the prefrontal cortex","volume":"24","author":"Sun","year":"2023","journal-title":"BMC Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0925","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-008-1072-4","article-title":"Realistic expectations of prepulse inhibition in translational models for schizophrenia research","volume":"199","author":"Swerdlow","year":"2008","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111249_bb0930","first-page":"512","article-title":"Expectancy effects in psychedelic trials","volume":"9","author":"Szigeti","year":"2024","journal-title":"Biol. Psych.: Cogn. Neurosci. Neuroimag."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0935","article-title":"Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL\/6J male mice","author":"Takaba","year":"2023","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"April","key":"10.1016\/j.pnpbp.2025.111249_bb0940","first-page":"1","article-title":"In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin","volume":"15","author":"Thomann","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb0945","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111249_bb0950","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41386-023-01545-z","article-title":"Acute psilocybin enhances cognitive flexibility in rats","volume":"48","author":"Torrado Pacheco","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111249_bb0955","first-page":"157","article-title":"Serotonin content of some mammalian tissues and urine and a method for its determination","volume":"175","author":"Twarog","year":"1953","journal-title":"Am. J. Phys."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111249_bb0960","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/FBP.0000000000000198","article-title":"Sex differences and serotonergic mechanisms in the behavioural effects of psilocin","volume":"27","author":"Tyl\u0161","year":"2016","journal-title":"Behav. Pharmacol."},{"issue":"17","key":"10.1016\/j.pnpbp.2025.111249_bb0965","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"NeuroReport"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111249_bb0970","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3390\/biom11121914","article-title":"5-HT Receptors and Temperature Homeostasis","volume":"11","author":"Voronova","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111249_bb0975","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0304-3940(98)00882-9","article-title":"mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons","volume":"258","author":"Vysokanov","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0980","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pnpbp.2017.04.008","article-title":"The recent progress in animal models of depression","volume":"77","author":"Wang","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111249_bb0985","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5694\/j.1326-5377.1964.tb133752.x","article-title":"Lysergic acid diethylamide in psychotherapy. Part I: clinical aspects","volume":"14","author":"Whitaker","year":"1964","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0990","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5694\/j.1326-5377.1964.tb133783.x","article-title":"Lysergic acid diethylamide in psychotherapy. Part II: results","volume":"21","author":"Whitaker","year":"1964","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.pnpbp.2025.111249_bb0995","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.40.4.228","article-title":"A biochemical and pharmacological suggestion about certain mental disorders","volume":"40","author":"Woolley","year":"1954","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pnpbp.2025.111249_bib1016","series-title":"Depressive disorder (depression)","year":"2024"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111249_bb1000","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions","volume":"75","author":"Ws\u00f3\u0142","year":"2023","journal-title":"Pharmacol. Rep."},{"issue":"February","key":"10.1016\/j.pnpbp.2025.111249_bb1005","article-title":"Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders","volume":"231","author":"Wulff","year":"2023","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111249_bb1010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.pnpbp.2025.111249_bb1015","series-title":"Psychiatry Research","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"vol. 335","author":"Yao","year":"2024"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858462500003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858462500003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:28:09Z","timestamp":1762284489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858462500003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":203,"alternative-id":["S027858462500003X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111249","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111249"}}